Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JNJ39758979
JNJ-39758979/ MTX · 2 trials · 2 indications
FEV1 will be measured by using spirometry test. Spirometry is used to measure lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Lung volumes will be measured according to the body temperature, pressure, and saturated standard convention using the spirometer. Pre-bronchodilator spirometry will be performed in the absence of albuterol/salbutamol or at least 6 hours after the last dose of albuterol/salbutamol.
To assess the effect of multiple doses of JNJ-39758979 on blood levels of methotrexate
| Arm | Type | Description |
|---|---|---|
| Treatment A (JNJ39758979) | EXPERIMENTAL | Participants will receive JNJ39758979 300mg once daily for 12 weeks. |
| Treatment B (Placebo) | PLACEBO_COMPARATOR | Participants will receive matching placebo once daily for 12 weeks. |
| 001 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ39758979 | DRUG | Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks. |
| Placebo | DRUG | Participants will receive matching placebo once daily orally for 12 weeks. |
| JNJ-39758979 / MTX | DRUG | Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily. |
Inclusion Criteria: * Confirmed diagnosis of asthma for at least 6 months * Short-acting beta-agonist use greater than or equal to 5 times in the 2 weeks prior to screening * Healthy on the basis of physical examination, medical history, vital signs, and 12 lead ECG performed at screening * Having ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
JNJ-39758979/ MTX refers to the small molecule JNJ-39758979 evaluated in combination with methotrexate (MTX) in rheumatoid arthritis. Johnson & Johnson developed the drug. It has been studied in a Phase 1 drug interaction trial with methotrexate and a Phase 2 trial in persistent asthma. The combination is investigational.
JNJ-39758979/ MTX has been studied for rheumatoid arthritis and asthma. The Phase 1 trial NCT01442545 examined how JNJ-39758979 affects methotrexate plasma levels in rheumatoid arthritis participants. The Phase 2 trial NCT00946569 evaluated JNJ-39758979 in adults with persistent asthma. Both indications remain investigational.
Johnson & Johnson, ticker JNJ, is the developer of JNJ-39758979 and the sponsor of its clinical trials, including the combination with methotrexate. The company conducted the Phase 1 methotrexate interaction study and the Phase 2 asthma study.
JNJ-39758979/ MTX has completed a Phase 1 trial and a Phase 2 trial. The Phase 1 study NCT01442545 investigated the effect of JNJ-39758979 on methotrexate plasma levels in rheumatoid arthritis. The Phase 2 study NCT00946569 tested JNJ-39758979 in persistent asthma. No active trials are ongoing.
JNJ-39758979/ MTX has been studied in two completed trials. NCT01442545 was a Phase 1 trial in rheumatoid arthritis that examined how JNJ-39758979 affects methotrexate plasma levels, enrolling 21 participants in the United States and Germany. NCT00946569 was a Phase 2 trial in persistent asthma, enrolling 116 participants across the United States, Canada, India, and Romania.